Role of Caspase 8, Caspase 9 and Bcl-2 polymorphisms in papillary thyroid carcinoma risk in Han Chinese population

Medical Oncology

Volumn 29, Issue 4, 2012, Pages 2445-2451

  Wang, Ying Xue ^a   Zhao, Lei ^b   Wang, Xiu Yun ^a   Liu, Chang Mei ^a   Yu, Su Guo ^a  

^a BINZHOU MEDICAL UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Bcl 2; Caspase 8; Caspase 9; Papillary thyroid carcinoma; Polymorphism

Indexed keywords

CASPASE 8; CASPASE 9; PROTEIN BCL 2;

ADULT; AGED; ARTICLE; CANCER RISK; CHINESE; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; THYROID CARCINOMA;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA; CASPASE 8; CASPASE 9; CHINA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROTO-ONCOGENE PROTEINS C-BCL-2; THYROID NEOPLASMS;

EID: 84867997442     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-0121-8     Document Type: Article

References (41)

1. Urken ML. Prognosis and management of invasive well-differentiated thyroid cancer. Otolaryngol Clin North Am. 2010;43(2):301-28. doi: 10.1016/j.otc.2010.02.002. viii.
2. Johnson NA, Tublin ME. Postoperative surveillance of differentiated thyroid carcinoma: rationale, techniques, and controversies. Radiology. 2008;249(2):429-44. doi: 10.1148/radiol.2492071313.
3. Kuma K, Matsuzuka F, Kobayashi A, Hirai K, Morita S, Miyauchi A, et al. Outcome of long standing solitary thyroid nodules. World J Surg. 1992;16(4):583-7. discussion 7-8.
4. Kuma K, Matsuzuka F, Yokozawa T, Miyauchi A, Sugawara M. Fate of untreated benign thyroid nodules: results of long-term follow-up. World J Surg. 1994;18(4):495-8. discussion 9.
5. Nikiforov YE. Is ionizing radiation responsible for the increasing incidence of thyroid cancer? Cancer. 2010;116(7):1626-8. doi: 10.1002/cncr.24889.
6. Hegedus L. Clinical practice. The thyroid nodule. N Engl J Med. 2004;351(17):1764-71. doi: 10.1056/NEJMcp031436.
7. Paschke R, Schmid KW, Gartner R, Mann K, Dralle H, Reiners C. Epidemiology, pathophysiology, guideline-adjusted diagnostics, and treatment of thyroid nodules. Med Klin (Munich). 2010;105(2):80-7. doi: 10.1007/s00063-010- 1011-9.
8. Dean DS, Gharib H. Epidemiology of thyroid nodules. Best Pract Res Clin Endocrinol Metab. 2008;22(6):901-11. doi: 10.1016/j.beem.2008.09.019.
9. Marx J. Oncology. Recruiting the cell's own guardian for cancer therapy. Science. 2007;315(5816):1211-3. doi: 10.1126/science.315.5816.1211.
10. Nakagawa A, Shi Y, Kage-Nakadai E, Mitani S, Xue D. Caspase-dependent conversion of Dicer ribonuclease into a death-promoting deoxyribonuclease. Science. 2010;328(5976):327-34. doi: 10.1126/science.1182374.
11. Shivapurkar N, Reddy J, Chaudhary PM, Gazdar AF. Apoptosis and lung cancer: a review. J Cell Biochem. 2003;88(5):885-98. doi: 10.1002/jcb.10440.
12. Hajra KM, Liu JR. Apoptosome dysfunction in human cancer. Apoptosis. 2004;9(6):691-704. doi: 10.1023/B:APPT.0000045786.98031.1d.
13. Wang W, Spitz MR, Yang H, Lu C, Stewart DJ, Wu X. Genetic variants in cell cycle control pathway confer susceptibility to lung cancer. Clin Cancer Res. 2007;13(19):5974-81. doi: 10.1158/1078-0432.CCR-07-0113.
14. Ye Y, Yang H, Grossman HB, Dinney C, Wu X, Gu J. Genetic variants in cell cycle control pathway confer susceptibility to bladder cancer. Cancer. 2008;112(11):2467-74. doi: 10.1002/cncr.23472.
15. Umar M, Upadhyay R, Kumar S, Ghoshal UC, Mittal B. CASP8-652 6 N del and CASP8 IVS12-19 G >A gene polymorphisms and susceptibility/prognosis of ESCC: a case control study in northern Indian population. J Surg Oncol. 2011;103(7):716-23. doi: 10.1002/jso.21881.
16. Sun T, Gao Y, Tan W, Ma S, Shi Y, Yao J, et al. A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. Nat Genet. 2007;39(5):605-13. doi: 10.1038/ng2030.
17. Haiman CA, Garcia RR, Kolonel LN, Henderson BE, Wu AH, Le Marchand L. A promoter polymorphism in the CASP8 gene is not associated with cancer risk. Nat Genet. 2008;40(3):259-60. doi: 10.1038/ng0308-259. author reply 60-1.
18. Gangwar R, Mandhani A, Mittal RD. Caspase 9 and caspase 8 gene polymorphisms and susceptibility to bladder cancer in north Indian population. Ann Surg Oncol. 2009;16(7):2028-34. doi: 10.1245/s10434-009-0488-3.
19. Czabotar PE, Lessene G. Bcl-2 family proteins as therapeutic targets. Curr Pharm Des. 2010;16(28):3132-48.
20. Park BL, Kim LH, Cheong HS, Cho HY, Kim EM, Shin HD, et al. Identification of variants in cyclin D1 (CCND1) and B-Cell CLL/lymphoma 2 (BCL2). J Hum Genet. 2004;49(8):449-54. doi: 10.1007/s10038-004-0173-0.
21. Bachmann HS, Otterbach F, Callies R, Nuckel H, Bau M, Schmid KW, et al. The AA genotype of the regulatory BCL2 promoter polymorphism (938 C>A) is associated with a favorable outcome in lymph node negative invasive breast cancer patients. Clin Cancer Res. 2007;13(19):5790-7. doi: 10.1158/1078-0432. CCR-06-2673.
22. Edge SB. American Joint Committee on Cancer. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.
23. Theodoropoulos GE, Michalopoulos NV, Panoussopoulos SG, Taka S, Gazouli M. Effects of caspase-9 and survivin gene polymorphisms in pancreatic cancer risk and tumor characteristics. Pancreas. 2010;39(7):976-80. doi: 10.1097/MPA.0b013e3181d705d4.
24. Zhang N, Li X, Tao K, Jiang L, Ma T, Yan S, et al. BCL-2 (-938 C>A) polymorphism is associated with breast cancer susceptibility. BMC Med Genet. 2011;12:48. doi: 10.1186/1471-2350-12-48.
25. Thatte U, Dahanukar S. Apoptosis: clinical relevance and pharmacological manipulation. Drugs. 1997;54(4):511-32.
26. Fennell DA. Caspase regulation in non-small cell lung cancer and its potential for therapeutic exploitation. Clin Cancer Res. 2005;11(6):2097-105. doi: 10.1158/1078-0432.CCR-04-1482.
27. Hengartner MO. The biochemistry of apoptosis. Nature. 2000;407(6805):770-6. doi: 10.1038/35037710.
28. Kaufmann SH, Gores GJ. Apoptosis in cancer: cause and cure. Bioessays. 2000;22(11):1007-17. doi: 10.1002/1521-1878(200011)22:11<1007:AID-BIES7>3. 0.CO;2-4.
29. Nicholson DW, Thornberry NA. Caspases: killer proteases. Trends Biochem Sci. 1997;22(8):299-306.
30. Mathew R, White E. FLIPping the balance between apoptosis and proliferation in thyroid cancer. Clin Cancer Res. 2006;12(12):3648-51. doi: 10.1158/1078-0432.CCR-06-0620.
31. Majid A, Tsoulakis O, Walewska R, Gesk S, Siebert R, Kennedy DB, et al. BCL2 expression in chronic lymphocytic leukemia: lack of association with the BCL2 938 A>C promoter single nucleotide polymorphism. Blood. 2008;111(2):874-7. doi: 10.1182/blood-2007-07-098681.
32. Kaderi MA, Norberg M, Murray F, Merup M, Sundstrom C, Roos G, et al. The BCL-2 promoter (-938 C>A) polymorphism does not predict clinical outcome in chronic lymphocytic leukemia. Leukemia. 2008;22(2):339-43. doi: 10.1038/sj.leu.2405042.
33. Zenz T, Benner A, Duhrsen U, Durig J, Dohner H, Siffert W, et al. BCL2-938 C>A polymorphism and disease progression in chronic lymphocytic leukemia. Leuk Lymphoma. 2009;50(11):1837-42. doi: 10.3109/10428190903207530.
34. Twiddy D, Cain K. Caspase-9 cleavage, do you need it? Biochem J. 2007;405(1):e1-2. doi: 10.1042/BJ20070617.
35. Park JY, Park JM, Jang JS, Choi JE, Kim KM, Cha SI, et al. Caspase 9 promoter polymorphisms and risk of primary lung cancer. Hum Mol Genet. 2006;15(12):1963-71. doi: 10.1093/hmg/ddl119.
36. Pittman AM, Broderick P, Sullivan K, Fielding S, Webb E, Penegar S, et al. CASP8 variants D302H and -652 6 N ins/del do not influence the risk of colorectal cancer in the United Kingdom population. Br J Cancer. 2008;98(8):1434-6. doi: 10.1038/sj.bjc.6604314.
37. Frank B, Rigas SH, Bermejo JL, Wiestler M, Wagner K, Hemminki K, et al. The CASP8-652 6 N del promoter polymorphism and breast cancer risk: a multicenter study. Breast Cancer Res Treat. 2008;111(1):139-44. doi: 10.1007/s10549-007-9752-z.
38. Young RL, Korsmeyer SJ. A negative regulatory element in the bcl-2 5′-untranslated region inhibits expression from an upstream promoter. Mol Cell Biol. 1993;13(6):3686-97.
39. Nuckel H, Frey UH, Bau M, Sellmann L, Stanelle J, Durig J, et al. Association of a novel regulatory polymorphism (-938 C>A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia. Blood. 2007;109(1):290-7. doi: 10.1182/blood-2006-03-007567.
40. Hirata H, Hinoda Y, Nakajima K, Kikuno N, Suehiro Y, Tabatabai ZL, et al. The bcl2-938CC genotype has poor prognosis and lower survival in renal cancer. J Urol. 2009;182(2):721-7. doi: 10.1016/j.juro.2009.03.081.
41. Lehnerdt GF, Franz P, Bankfalvi A, Grehl S, Kelava A, Nuckel H, et al. The regulatory BCL2 promoter polymorphism (-938 C>A) is associated with relapse and survival of patients with oropharyngeal squamous cell carcinoma. Ann Oncol. 2009;20(6):1094-9. doi: 10.1093/annonc/mdn763.